N/A N=5 A Translational Approach to Gitelman Syndrome
Gitelman Syndrome
Primary: Chloriuretic Response to a Thiaizde — 1.23 fractional chloride excretion
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=61 Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate
Hypertension
Primary: Change in Fasting Plasma Glucose From Week 4 to Week 16 — -5.6; 2.3 mg/dL
Phase 1 N=38 Aldosterone and the Metabolic Syndrome
Metabolic Diseases · Diabetes Mellitus · Endocrine System Diseases
Primary: Plasma Insulin — 75.4; 50.1; 43.5; 114.0 uU/ml
Phase 2 N=160 Chlorthalidone in Chronic Kidney Disease
Renal Insufficiency, Chronic · Hypertension
Primary: Change From Baseline to 12 Weeks in Systolic Ambulatory Blood Pressure in the Chlorthalidone Group Compared to Placebo. — -11.0; -0.5 mm Hg
Phase 4 N=124 Salt Loading and Thiazide Intervention Study
Hypertension
Primary: Blood Pressure Change During Salt Loading — -25.5; 34.6; 23.2; -41.4 mmHg — p=>0.05
Phase 2 N=34 Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial
Renal Insufficiency, Chronic
Primary: Change in Total Body Water — -0.075; -4.36 litres — p=<0.001
Phase 2 N=15 Calcium Channel Blockade in Primary Aldosteronism
Primary Aldosteronism · Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)
Primary: Change in 24-hour Urinary Aldosterone Excretion Rate — 0.21 mcg/24h — p=0.96
N/A N=92 Renin-angiotensin-aldosterone System Polymorphisms in Resistant Hypertension and Adverse Cardiovascular Events
Systemic Arterial Hypertension · Hypertension Resistant to Conventional Therapy · Myocardial Infarction
Primary: Strokes, Either Fatal or Nonfatal — 24; 7 participants — p=0.19
Phase 4 N=14 A Pilot Study of Chlorthalidone Among Patients With Poorly Controlled Hypertension and CKD
Chronic Kidney Disease · Poorly-Controlled Hypertension
Primary: Change of Systolic Ambulatory Blood Pressure From Baseline to 12 Weeks — -10.5 mmHg — p=0.01
Phase 2 N=10 The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study
Cystinuria
Primary: 24hr Urine Measurements of the Effect of SGLT-2 Inhibitor Therapy on Cystine Production in Urine in Patients With Cystinuria — 999.3 24hr urine cystine concentration…
Phase 2 N=30 Role Of Phosphorus And FGF 23 In Patients With Dent Disease
Dent Disease
Primary: Change in Urine Total Protein — 1681; 59 mg/day
N/A N=23 Aldosterone and Glucose Homeostasis
Diabetes Mellitus
Primary: Insulin Secretion — 48.9; 37.6; 51.8; 34.4 uU/mL
Phase 4 N=90 Mineralocorticoid Receptor (MR) Antagonist (Eplerenone) vs Amlodipine and STRIATIN
Hypertension · Genetics Hypertension
Primary: Systolic /Diastolic Supine Morning Liberal Salt Automated Blood Pressure — 144.2; 148.5; 86.0; 91.4 mm hg — p=0.823
Phase 4 N=10 Effect of Licorice and Hydrochlorothiazide on Plasma Potassium
Hypokalemia
Primary: Plasma Potassium — 4.0; 4.0; 4.1; 3.7 mmol/l — p=0.007
Phase 2 N=295 Spironolactone With Patiromer in the Treatment of Resistant Hypertension in Chronic Kidney Disease
Hyperkalemia · Resistant Hypertension
Primary: Number of Participants Remaining on Spironolactone at Week 12 — 126; 98 Participants — p=<0.0001
Phase 4 N=1 Diltiazem in Jervell and Lange-Nielsen Syndrome
Jervell and Lange Nielsen Syndrome
Primary: QT Interval — 623 ms
Phase 2 N=306 Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)
Chronic Kidney Disease · Hypertension · Hyperkalemia
Primary: Least Squares Mean Change in Serum Potassium From Baseline to Week 4 or Time of First Titration for Each Individual Starting Dose Group — -0.35; -0.51; -0.55; -0.87…
Phase 2 N=59 Tissue Sodium in Pre-hypertensive Patients
Hypertension
Primary: Change in Tissue Sodium Concentration Measured Using Sodium Magnetic Resonance Imaging (NaMRI) — -0.202; 0.430; -1.745; -0.407 mmol/L